Who are Peginterferon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Saphnelo, Besremi, Plegridy, Pegasys, Avonex, Betaseron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peginterferon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Peginterferon — Competitive Intelligence Brief

Peginterferon (Peginterferon) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon beta [EPC]. Area: Infectious Disease.

marketed Interferon beta [EPC] Interferon alpha/beta receptor Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Peginterferon (Peginterferon) — Ziv Hospital.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Peginterferon TARGET	Peginterferon	Ziv Hospital	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor
Saphnelo	ANIFROLUMAB	AstraZeneca	marketed	Type I Interferon Receptor Antagonist [EPC]	Interferon alpha/beta receptor 1	2021-01-01
Besremi	ROPEGINTERFERON ALFA-2B	Pharma Essentia Corporation	marketed	Interferon alfa-2b [EPC]	Interferon alpha/beta receptor	2021-01-01
Plegridy	PEGINTERFERON BETA-1A	Biogen Idec Inc	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	2014-01-01
Pegasys	PEGINTERFERON ALFA-2A	Hoffman-La Roche	marketed		Interferon alpha/beta receptor	2002-01-01
Avonex	INTERFERON BETA-1A	Biogen	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	1996-01-01
Betaseron	INTERFERON BETA-1B	Bayer Healthcare Pharms	marketed	Interferon beta	Interferon alpha/beta receptor	1993-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon beta [EPC] class)

Biogen · 1 drug in this class
Biogen Idec Inc · 1 drug in this class
Ziv Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peginterferon — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab